Structural insight into the recognition of pathogen-derived phosphoglycolipids by C-type lectin receptor DCAR

Zakaria Omahdi, a,b,c Yuto Horikawa, a Masamichi Nagae, a,b,c Kenji Toyonaga, a,b Akihiro Imamura, b,g Koichi Takato, a Takamasa Teramoto, a Hideharu Ishida, a,b,c Yoshimitsu Kakuta, d,h,1 and Sho Yamasaki e,f,g,h,i

From the aDepartment of Molecular Immunology, Research Institute for Microbial Diseases and the bLaboratory of Molecular Immunology, Immunology Frontier Research Center (IFReC), Osaka University, Suita 565-0871, Japan, the cDepartment of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan, the dLaboratory of Structural Biology, Graduate School of System Life Sciences and the eDepartment of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Moto-oka, Nishi-ku, Fukuoka 819-0395, Japan, the fDepartment of Applied Bioorganic Chemistry, Faculty of Applied Biological Sciences, the gUnited Graduate School of Agricultural Science, and the hCenter for Highly Advanced Integration of Nano and Life Sciences, Gifu University, Gifu 501-1193, Japan, the iDivision of Molecular Design, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan, and the jDivision of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba 260-8673, Japan

Edited by Gerald W. Hart

The C-type lectin receptors (CLRs) form a family of pattern recognition receptors that recognize numerous pathogens, such as bacteria and fungi, and trigger innate immune responses. The extracellular carbohydrate-recognition domain (CRD) of CLRs forms a globular structure that can coordinate a Ca\(^{2+}\) ion, allowing receptor interactions with sugar-containing ligands. Although well-conserved, the CRD fold can also display differences that directly affect the specificity of the receptors for their ligands. Here, we report crystal structures at 1.8–2.3 Å resolutions of the CRD of murine dendritic cell-immunoactivating receptor (DCAR, or Clec4b1), the CLR that binds phosphoglycolipids such as acylated phosphatidyl-myoinositol mannosides (AcPIMs) of mycobacteria. Using mutagenesis analysis, we identified critical residues, Ala\(^{136}\) and Gln\(^{198}\), on the surface surrounding the ligand-binding site of DCAR, as well as an atypical Ca\(^{2+}\)-binding motif (Glu-Pro-Ser/EPS\(_{168-170}\)). By chemically synthesizing a water-soluble ligand analog, inositol-monophosphate dimannose (IPM2), we confirmed the direct interaction of DCAR with the polar moiety of AcPIMs by biolayer interferometry and co-crystallization approaches. We also observed a hydrophobic groove extending from the ligand-binding site that is in a suitable position to interact with the lipid portion of whole AcPIMs. These results suggest that the hydroxyl group-binding ability and hydrophobic groove of DCAR mediate its specific binding to pathogen-derived phosphoglycolipids such as mycobacterial AcPIMs.

The recognition of pathogens by the innate immune system is one of the initial steps leading to a robust and well-orchestrated immune response (1). This physiological process is in part made possible by the presence of proteins at the surface of the immune cell called pattern-recognition receptors. Among these, C-type lectin receptors (CLRs)\(^3\) form a family of pattern recognition receptors that were shown to recognize not only a broad spectrum of pathogens, but also endogenous molecules released by stressed or dying cells, through their interaction with ligands of various types and structures (2–4). Most of these receptors share the same domain organization: they are type II transmembrane proteins with a cytoplasmic intracellular tail, a transmembrane domain, and an extracellular domain composed of both the stalk region as well as the compact and globular carbohydrate-recognition domain (CRD) (5). Through its ability to coordinate Ca\(^{2+}\) ions, the CRD is, for most CLRs, of paramount importance to bind sugar-containing ligands.

Dendritic cell immunoactivating receptor (DCAR, or Clec4b1) is a CLR expressed by myeloid cells that was originally described by high sequence similarity with dendritic cell immunoceptor 1 (DCIR1, or Cleca2a) in mouse (6). Although they share 91% similarity in their CRDs, differences were observed in their stalk and intracellular domains. Contrarily to DCIR1, which has an immunoreceptor tyrosine-based inhibitory motif (ITIM) within its own intracellular domain, the adaptor mole-
Crystal structure of C-type lectin receptor DCAR

cule Fc receptor γ chain (FcRγ) harboring an immunoreceptor tyrosine-based activation motif (ITAM) is required for DCAR-dependent signaling (6, 7).

We recently reported that DCAR functions as a receptor for mycobacteria through the recognition of unique phosphoglycolipids abundantly found in mycobacterial envelopes, called acylated phosphatidyl-\(\text{myo-inositol}\) mannosides (AcPIMs) (8). This induces MCP-1 production from monocyte-derived inflammatory cells and promotes a Th1-mediated protective response, thereby contributing to the immune response against mycobacteria in mouse (7). However, the molecular and structural basis of phosphate-containing glycolipid recognition by DCAR remains to be clarified. Human DCIR and blood dendritic cell antigen 2 (BDCA-2) are closely related to DCAR, but its own human ortholog has yet to be identified (9, 10). However, AcPIMs induce similar sets of inflammatory genes in human dendritic cells (7), implying that humans express unidentified AcPIM receptor, and thus the determination of murine DCAR structure may provide valuable information for the identification of novel bacterial receptor(s). The present study shows that DCAR has an overall typical C-type lectin fold that allows it to bind carbohydrates in similar fashion to other CLRs. Structural and mutagenesis analysis also revealed its characteristics for the suitable recognition of unique mycobacterial phosphoglycolipids.

Results

DCAR preparation, crystallization, and structural determination

The CRD (residues 78–209) of murine DCAR was expressed as inclusion bodies in Escherichia coli and then refolded in vitro by a dilution method. Refolding of DCAR did not require Ca\(^{2+}\) ions, and refolded proteins were purified by anion exchange followed by gel-filtration chromatography (Fig. 1A and B). The elution profile of the refolded CRD displayed a single homogenous and sharp peak at the expected molecular weight, indicating that conformational variations were unlikely and that the CRD behaves as a monomer after refolding (Fig. S1A). DCAR CRD crystals were obtained by the sitting-drop method, the structure was solved at a resolution of 2.3 Å, and the asymmetric unit contained two DCAR molecules (Table 1). The structure of DCAR is composed of two flanking antiparallel α-helices (α1 and α2) and nine β-strands (β1 to β9) and is stabilized by three disulfide bonds similar to other CLR family members (Fig. 1). These results thus show that DCAR has an overall typical C-type lectin domain fold.

Structural comparison of DCAR and Mincle

The CRD of the similar CLR Mincle (Fig. 2B), which has been determined as the disaccharide trehalose complex, has 43% sequence similarity with the CRD of DCAR (Fig. 2A) and was used for structural comparison (11). Superimposition of DCAR and cow Mincle (Fig. 2B; PDB code 4ZRW) shows that the position of backbone Ca atoms in both CRDs are similar, with a root-mean-square deviation of 0.627 Å for 129 structurally equivalent Ca atoms (Fig. 2C). Although Mincle binds three ions, whereas DCAR binds only one, the position of the Ca\(^{2+}\) ion of the primary sugar-binding site is also nearly the same between the two proteins (Fig. 2, A–C). The canonical EPN (Glu-Pro-Asn) motif of the primary sugar-binding site of Mincle (residues 168–170) is typically found in glucose/man- nose binding CLRs, as opposed to the QPD (Gln-Pro-Asp) motif, which generally indicates a preference toward galactose-containing ligands (5, 12). DCAR bears a similar but unusual EBS (Glu-Pro-Ser) sequence (residues 168–170), also found in several members of the DCIR family (13). As shown by the crystal structure of hDCIR (PDB code 5B1X), the EBS sequence can successfully coordinate a Ca\(^{2+}\) ion and contribute to mannose recognition (13). In line with this report, DCAR also bound a Ca\(^{2+}\) ion through its EBS sequence, as well as two additional residues of the WND motif (residues 189–191) which is well-conserved among CLRs (Figs. 1, green filled circles, and 2D). Despite this sequence difference, the Ca\(^{2+}\)-binding site location and the position of the amino acids of DCAR and Mincle are nearly identical (Fig. 2, D–F), with the exception of the residues following the EBS motif in Mincle that interact with another Ca\(^{2+}\) ion and are protruding compared with the corresponding amino acids of DCAR (Fig. 2C). The overall structural comparison therefore confirms that the CRD of DCAR has a typical C-type lectin domain fold and can coordinate a Ca\(^{2+}\) ion through its EBS sequence.

The EPS motif of DCAR is required for optimal function

As mentioned above, DCAR coordinates its Ca\(^{2+}\) ion through an EBS sequence, which was shown to mediate man-

---

**Table 1**

| Data collection and refinement statistics. |
|-------------------------------------------|
| **Ligand-free**                         | **Glycosyl complex** | **IPM2 complex** |
| Space group                              | \(P2_1,2,1\)         | \(P2_1,2,1\)     | \(P2_1,2,1\)     |
| Unit cell parameters (Å)                 |                      |                  |
| \(a\)                                    | 64.4                 | 66.0             | 65.7             |
| \(b\)                                    | 72.1                 | 72.4             | 72.6             |
| \(c\)                                    | 100.6                | 101.1            | 100.5            |
| Wavelength (Å)                           | 1.0000               | 1.0000           | 1.0000           |
| Resolution range (Å)                     | 50.0–1.85            | 58.9–2.30        | 48.8–1.84        |
| No. of reflections                       | 268,974              | 158,838          | 280,261          |
| Unique                                   | 77,390               | 22,007           | 80,659           |
| Redundancy                               | 3.5 (3.5)            | 7.2 (7.2)        | 3.5 (3.3)        |
| \(R_{	ext{merge}}\) (overall/outer shell) | 0.084 (0.817)        | 0.120 (0.687)    | 0.143 (0.800)    |
| \(I/\sigma(I)\)                          | 10.9 (1.27)          | 15.1 (3.00)      | 5.60 (1.00)      |
| CC\(_{100}\) (%)                         | 99.8 (95.9)          | 99.7 (98.6)      | 99.6 (99.4)      |

**Refinement statistics**

| Resolution range (Å)                     | 48.1–1.84            | 44.0–2.30        | 48.8–1.84        |
| No. of reflections                       | 38,931               | 20,861           | 40,178           |
| Working set                              | 1999                 | 1141             | 1981             |
| Test set                                 | 97.94                | 99.72            | 99.45            |
| Completeness (%)                         | 18.2/20.5            | 14.7/21.2        | 16.0/20.4        |
| Root mean square deviation               | 0.013                | 0.013            | 0.013            |
| Bond angles (°)                          | 1.634                | 1.629            | 1.674            |
| Average B-factor (Å\(^2\))/no. of atoms | 37.19/2331           | 35.52/2261       | 31.31/2312       |
| Protein                                  | 36.99/2               | 23.98/2         | 34.66/2         |
| Ca\(^{2+}\)                               | 46.03/235            | 47.05/243       | 43.25/290       |
| Water                                    | 43.23/24             | 43.25/24        | 43.25/24        |
| Glycerol                                 | 71.39/65             | 59.28/19        | 59.28/19        |
| IPM2                                     | 58.58/19             | 59.28/19        | 59.28/19        |
| Bis–Tris–propane                         | 89.70                | 90.91            | 91.18            |
| Ramachandran analysis                    | 8.15                 | 7.44             | 5.88             |
| Favored (%)                              | 2.15                 | 1.65             | 2.94             |

---

5808  J. Biol. Chem. (2020) 295(17) 5807–5817

ASBMB
nose binding by hDCIR (13). This sequence is also found in two other members of the DCIR family. We thus sought to test whether this unusual EPS sequence is necessary for ligand binding by DCAR. For comparison, we generated a DCAR–Ig fusion protein, composed of the Fc portion of human IgG fused to the extracellular domain of DCAR (stalk and CRD), which bears the well-established EPN motif instead of the EPS sequence (DCAREPN–Ig). Binding of DCAR EPN–Ig to plate-coated AcPIM2 was significantly reduced when compared with DCAR–Ig (Fig. S2A). An even stronger decrease in signaling activity was observed when stimulating reporter cells expressing the DCAR<sup>EPN</sup> mutant with AcPIMs (Fig. S2B). These results thus indicate that the EPS sequence is indeed a Ca<sup>2+</sup>-binding motif and necessary for optimal ligand binding and signaling through DCAR. Furthermore, an additional electron density corresponding to a glycerol molecule is observed adjacent the Ca<sup>2+</sup> coordination site (Fig. 3A, left panel), and the comparison with the location of trehalose in the structure of Mincle (PDB code 4KZV) showed that the two OH groups of glycerol were in a similar position to that of the 3- and 4-OH groups of trehalose (Fig. 3B) (14). Furthermore, we also observed two H<sub>2</sub>O molecules in the same position in the ligand-free DCAR crystals grown in a glycerol-free condition (Fig. S3A). These results suggest that DCAR, through its atypical EPS motif, interacts with the sugar moiety of its ligands.

**Ligand recognition requires the short and neutral residue Ala<sup>136</sup>**

Unlike the conserved residues of the Ca<sup>2+</sup>-coordinating site, the ones surrounding it are rather different between DCAR and Mincle (Fig. 3B). Among these, we first assessed the role of the Ala<sup>136</sup> (Glu<sup>135</sup> in Mincle) by mutagenesis. Because DCAR ligands bear a negatively charged phosphate (7), we surmised that, contrarily to Mincle, the non-negative and relatively short side chain of Ala<sup>136</sup> was required to accommodate a phosphate moiety in this area. We therefore introduced a negatively charged Glu (the corresponding residue of Mincle; DCARA<sup>136E</sup>) or Asp (DCARA<sup>136D</sup>) at this position and induced the expression of the mutant receptors in reporter cells. The presence of a negatively charged residue at this position as is the case for Mincle, abolished GFP expression in response to ligand stimulation (Fig. 3C), implying that a negative charge in the vicinity of the primary sugar-binding site may prevent the interaction with AcPIMs. To examine the impact of the size of the side chain, we substituted the neutral Ala<sup>136</sup> with neutral residues of increasing side-chain length (Val<sup>136</sup>/Ile). Although the mutant with the shortest residue (DCARA<sup>136V</sup>) retained significant reporter activity, the DCARA<sup>136L</sup> and DCARA<sup>136I</sup> mutants showed strongly reduced activation (Fig. 3D). These results were confirmed by the introduction of these mutations in DCAR–Ig fusion proteins, which had a similar effect on direct binding to plate-coated AcPIMs (Fig. 3E and Fig. S2C). It thus suggests that the Ala<sup>136</sup> is required to avoid electrostatic and steric hindrance with the phosphate moiety of AcPIMs.

**Critical role of Gln<sup>198</sup> for ligand binding**

The residues corresponding to the Gln<sup>198</sup> of DCAR (Fig. 3B) in mDCIR2, hDCIR, and hDectin-2 (His<sup>225</sup>, Gln<sup>226</sup>, and Arg<sup>198</sup>, respectively) were shown to be part of a secondary sugar-binding site in these three closely related CLRs (13, 15, 16). Consistent with these results, Gln<sup>198</sup> was shown to be required for DCAR, because substitution with Ala and the slightly shorter Asn both abolished binding efficiency (Fig. S2D). Moreover, the strong reduction of binding induced by introducing a Glu at
this position confirmed the detrimental effect of a negative charge near the primary sugar-binding site, as seen for Ala136 (Fig. S2D).

In hDCIR, hBDCA-2, and mDCIR2, an Asn corresponds to the Tyr180 of DCAR and interacts with the carbonyl group of the N-acetylglucosamine (GlcNAc) at the nonreducing end of mannose in all three structures (13, 15, 17, 18). Mutation of Tyr180 led to a partial reduction of reporter activity (Fig. S2E), suggesting that this residue is also involved in binding, but to a lesser extent than the Gln198. Collectively, these results may therefore imply that DCAR binds an additional sugar of its ligands through a secondary sugar-binding site.

DCAR binds the phosphosaccharide moiety of AcPIMs

Among CLR s, DCAR has the uncommon characteristic of recognizing and binding phosphoglycolipids from mycobacteria such as AcPIM2 (Fig. 4A). We thus sought to investigate whether the sugar and phosphate moiety interacts with DCAR. We generated a soluble synthetic compound that comprises the phosphosaccharide moiety of AcPIM2 without lipid chains (inositol-monophosphate dimannose; IPM2), which can be used in aqueous binding assays (Fig. 4A, shaded in blue). We first attempted to inhibit binding of the DCAR–Ig fusion protein to plate-coated AcPIM2 by this analog (Fig. 4A). Contrary to free D-mannose, this compound induced a dose-dependent inhibition of DCAR–Ig binding to its ligand. These results suggest that DCAR has the potential to interact with at least mannose linked to inositol monophosphate.

To measure direct binding of DCAR–Ig to the analog IPM2, we turned to the sensitive biolayer interferometry (BLI) assay. Neither free mannose nor free D-my o-inositol (data not shown) could be bound by DCAR–Ig. Consistent with the competitive binding assay shown in Fig. 4A, real-time binding of DCAR–Ig, but not Ig, to the synthetic PIM analog was observed by BLI (Fig. 4B, left panels). In this experimental setting, steady-state analysis (Fig. 4B, right panels) demonstrated a dissociation constant ($K_d$) of $140 \pm 7.9 \mu M$. This result therefore indicated that within the whole ligand, DCAR has substantial affinity with the phosphosaccharide moiety.

DCAR complex structure with IPM2

We finally tried to verify this interaction by obtaining the structure of DCAR in complex with IPM2 (Fig. 5A). Co-crystals of the DCAR CRD–IPM2 complex were diffracted up to 1.84 Å.
resolution in the $P2_1\bar{2}1_2$ space group, and two complexes were in the asymmetric unit. The electron density of IPM2 was clearly identified except for one mannose (Fig. 5B). The structure shows that DCAR interacts with mannose through the 3- and 4-OH groups (Fig. 5A), which confirms our assumption raised from the interaction with glycerol (Fig. 3A) and that DCAR binds mannose through its EPS motif. Importantly, we did not observe apparent conformational change upon ligand binding, which is often seen in “non-CLR” immune receptors (19, 20). Rather, ligand-free and IPM2-bound structures of DCAR were almost identical (Fig. 5C–E), supporting the idea that CLR receptors do not utilize conformational changes as a strategy for signaling.

**Contribution of a hydrophobic groove to the interaction with AcPIMs**

Our analysis of DCAR binding to IPM2 by BLI showed that the interaction dissociated rapidly (Fig. 4B). This prompted us to determine whether another determinant may be involved in the interaction with the whole “acylated” ligands AcPIMs. The crystal structure revealed a hydrophobic area close to the IPM2-binding site (Fig. 6A and B), which is in a suitable position to accommodate the acyl chains of AcPIMs. We therefore reduced the hydrophobicity of this area by substituting the Ile$^{133}$ by Gly (DCARI$^{133}$G) or Ala (DCARI$^{133}$A). The DCAR reporter activity was strongly reduced for both mutants (Fig. 6C), whereas these mutations did not grossly disrupt the receptor structure and function (Fig. 6D). These results thus suggest that this hydrophobicity also contributes to the recognition of the mycobacterial AcPIMs via its receptor DCAR.

**Discussion**

We report here the atomic details of unique ligand recognition mode of the CRD of DCAR toward phosphoglycolipids. The Ca$^{2+}$-binding motifs of C-type lectins were shown to directly influence sugar specificity. Indeed, substituting the...
EPN motif of rat MBP-A (mannose-binding protein A) by QPD imparts galactose binding ability to this C-type lectin (12). Although the EPN and EPS motifs both have previously been shown to bind mannose moieties (5, 13), here we show that having an EPN motif in lieu of EPS significantly reduces ligand recognition by DCAR. Interestingly, the amine group of Asn170 of EPN168–170 makes a hydrogen bond with the 3-OH of glucose in the Mincle–trehalose complex (Fig. 3A, right panel), but the Ser170 in EPS168–170 of DCAR does not have this hydrogen donor (Fig. 5A and Fig. S3B). It may therefore be plausible that the EPS motif sets the ligand in a different position than the EPN, which could contribute to efficient ligand binding by DCAR. Thus, the C-type lectins may have evolved to recognize a broader spectrum of ligands by mutational changes in their binding motifs while retaining their overall canonical fold. Indeed, several unconventional EPN-like motifs, such as EPS and EPK, are found in C-type lectins across species (5, 10, 21, 22).

DCAR belongs to the DCIR family of CLRs, which share structural and ligand-binding similarities. Among them, the secondary binding site of hBDCA-2 and mDCIR2 interacts with GlcNAc linked to mannos (13, 15, 17). The Asn184 and Arg186 of hBDCA-2 interact with the carbonyl group of GlcNAc. Although the Arg (residue 182) is conserved in DCAR, the res-
idue corresponding to the Asn of hBDCA-2 is Tyr180. Therefore, the hydrogen bond network with GlcNAc seen in hBDCA-2 would not be feasible for DCAR. mDCIR2 also binds GlcNAc through two additional residues (Asp223 and His225), but they are not conserved in DCAR. This shows that although DCAR shares structural similarities with DCIR family members, it possesses fine characteristic structural features to achieve its unique specificity.

The loop region between the β2 and β3 strands of mDCIR2 was suggested to create a narrow carbohydrate-binding site when compared with dendritic cell–specific ICAM-3 grabbing nonintegrin (DC-SIGN), which would lead to lower affinity for high mannose ligands. It was also proposed that this may be a conserved feature among DCIR family members (15). Interestingly, we have previously shown that among the AcPIM species, which vary in their number of mannose residues, DCAR activation and binding weakens as the number of mannose increases (Fig. S4A), whereas the opposite tendency was observed for DC-SIGN (Fig. S4B) (7). Because the β6-β7 loop of DCAR also generates a narrow binding site when compared with that of DC-SIGN (Fig. S4C), it could explain DCAR poor binding to AcPIM6 and AcPIM6. Our data therefore corroborate this hypothesis, and the characteristic narrow carbohydrate-binding site may indeed be shared by DCIR family CLRs, which may contribute to their specificity for low mannose ligands.

Our complex analysis clearly demonstrated the interaction of mannose to DCAR. Although inositol and phosphate were not observed in the proximity of the CRD from the co-crystal structure with IPM2, it does not exclude the possible contribution of phosphate and inositol in the context of whole AcPIMs. Indeed, our BLI analysis suggests that DCAR can interact with the phosphosaccharide IPM2 but not with mannose alone. Similarly, IPM2, but not monosaccharide, was able to block the interaction between DCAR and AcPIM2 (Fig. 4A). However, the interaction of DCAR CRD and IPM2 was transient and dissociated rapidly, implying that another additional determinant also contributes to stable interaction, which may be required for optimal signal transduction through DCAR. Mincle was shown to have a hydrophobic region close to the primary sugar-binding site that allows the accommodation of the lipid moiety of its ligands (11, 23). The structure of DCAR also shows a hydrophobic surface, although in a different area than that of Mincle, extending from the primary sugar-binding site (Fig. 5, A and B), which also contributed to the AcPIM binding (Fig. 6C).

Our complex analysis clearly demonstrated the interaction of mannose to DCAR. Although inositol and phosphate were not observed in the proximity of the CRD from the co-crystal structure with IPM2, it does not exclude the possible contribution of phosphate and inositol in the context of whole AcPIMs. Indeed, our BLI analysis suggests that DCAR can interact with the phosphosaccharide IPM2 but not with mannose alone. Similarly, IPM2, but not monosaccharide, was able to block the interaction between DCAR and AcPIM2 (Fig. 4A).

However, the interaction of DCAR CRD and IPM2 was transient and dissociated rapidly, implying that another additional determinant also contributes to stable interaction, which may be required for optimal signal transduction through DCAR. Mincle was shown to have a hydrophobic region close to the primary sugar-binding site that allows the accommodation of the lipid moiety of its ligands (11, 23). The structure of DCAR also shows a hydrophobic surface, although in a different area than that of Mincle, extending from the primary sugar-binding site (Fig. 6, A and B), which also contributed to the AcPIM binding (Fig. 6C).

Acylated PIMs may have up to four acyl chains; there are two within the phosphatidyl moiety, and for AcPIM2, one additional chain is linked to the 6-OH of the Man2 residue (Fig. 4A). Based on the DCAR–IPM2 complex, one mannose residue is bound at the primary sugar-binding site, and its 6-OH would be in a suitable position to allow an acyl chain to interact with the
hydrophobic groove (Fig. 6B). Additionally, the position of the phosphate group of IPM2 suggests that the phosphatidyl moiety may also be bound by the hydrophobic area, which could bring the phosphate and inositol within interacting distance of Ala136, Tyr180, and Gln198. This may explain the strong reduction of ligand binding by mutation of these residues observed in response to whole AcPIMs. Thus, these two lectins for mycobacteria may have independently acquired the structural feature conferring the ability to recognize not only sugars but also lipids, because the primary structure corresponding to the putative hydrophobic grooves were different between Mincle and DCAR.

Signaling through C-type lectin receptors requires their multimerization by the recognition of multivalent ligands, thereby inducing the phosphorylation of ITAM within their signaling subunits (24, 25). Therefore, theoretically these receptors do not necessarily require ligand-induced conformational change, which is usually a critical process for other receptors, such as cytokine receptors or G protein–coupled receptors. Indeed, we did not observe any drastic conformational changes of DCAR CRD after IPM2 binding (Fig. 5, C and D). Thus, although DCAR is able to recognize one ligand molecule, AcPIMs can signal through DCAR only when it is presented on the bacteria at high valency. This may be an additional strategy to discriminate real pathogens from the presence of structurally similar glycolipids that should not trigger immune responses in the host. Indeed, IPM2 did not activate cells expressing DCAR (data not shown), although it bound to DCAR (Fig. 4B).

The structural analysis of DCAR revealed particular features allowing this receptor to bind phosphate-containing ligands, implying the presence of other pathogen- or host-derived phosphoglycolipids recognized by this CLR. Because no homolog of DCAR was found in the human Dectin-2 cluster, the structure of mouse DCAR may contribute to a rational structural approach toward the identification of a functional homolog or unknown receptor(s) for AcPIMs in human.

Experimental procedures

Reagents

AcPIM2 and Ac2PIM2 were purified from mycobacterial crude lipids as described previously (7). Anti-mouse DCAR rat mAb (MAB2757, clone 349214) was purchased from R&D Systems.

Recombinant protein expression and purification

The CRD of mouse DCAR (residues C78-L209) was inserted in the E. coli expression plasmid pGMT7 (primers are shown in Table S1), which then was transformed into the E. coli strain
Rosetta™ (DE3) (Novagen). Because of a cloning artifact, three additional amino acids were expressed at the N-terminal end upstream of the C78. Transformants were grown in selective LB medium, protein expression was induced with 0.5 mM isopropyl β-D-thiogalactoside (Nacalai Tesque Inc.), and the cells were cultured for 3 h. The cells were then harvested at 4000 rpm for 20 min, resuspended in lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 150 mM NaCl, 10% glycerol) and disrupted by sonication. After a 30-min DNase I (Roche, 100 μg/ml) treatment, inclusion bodies were purified by centrifugation. Inclusion bodies were solubilized in a buffer containing 6 M guanidine, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA. DTT (10 mM) was then added to solubilized proteins, which were then slowly incorporated into a refolding buffer containing 100 mM Tris-HCl, pH 8.0, 2 mM EDTA, 0.4 M l-arginine, 6.5 mM cysteamine, 3.6 mM cystamine and slowly stirred at 4 °C for at least 3 h. The proteins were then dialyzed twice against 10 mM Tris-HCl, pH 8.0, and purified by anion exchange (Poros® 50 HQ column, Applied Biosystems) and size-exclusion (Superdex™ 200 10/300 column, GE healthcare) chromatography. The fractions corresponding to the DCAR CRD were pooled and enriched using an Amicon Ultra centrifugal filter (molecular weight cutoff: 3000, Merck Millipore) for crystallization assays.

**Crystallization and structure determination**

All crystals were generated by crystallizing purified recombinant DCAR (10 mg/ml for ligand-free and DCAR–IPM2 complex and 13 mg/ml for DCAR–glycerol complex) using the sitting-drop vapor-diffusion method at 20 °C. DCAR–glycerol complex crystals were obtained by growing crystals for 4 days under a reservoir solution consisting of 0.04 M citric acid, 0.06 M Bis-Tris propane, pH 6.4, 20% (w/v) PEG 3350, 10 mM CaCl₂. For data collection, the crystals were transferred to the cryo buffer (0.04 M citric acid, 0.06 M Bis-Tris propane, pH 6.4, 22% (w/v) PEG 3350, 10 mM CaCl₂, 15% glycerol). Ligand-free and DCAR–IPM2 complex crystals were grown for 7 days under a reservoir solution consisting of 0.04 M citric acid, 0.06 M Bis-Tris propane, pH 6.4, 35% (w/v) PEG 3350, 10 mM CaCl₂, with or without 120 mM IPM2. For data collection, the crystals were frozen directly from the drop in liquid nitrogen. Thereafter, all crystals were flash-frozen using a cryo system (Rigaku). X-ray diffraction data sets were collected on Beamline BL45XU at SPring-8 (Hyogo, Japan). The diffraction data were processed using the program package XDS (26). The crystals were found to belong to space group P2₁2₁2₁. The data collection statistics are compiled in Table 1. The crystal structure of the DCAR–glycerol complex was determined by molecular replacement using Molrep (27) with the template structure (PDB code 3VYJ), and the ligand-free and IPM2-complex structures were obtained by molecular replacement using the glycerol-complex structure. The structures were manually modified using the Coot program (28). Several iterative rounds of model building were performed in Coot and refined using Refmac5 (29). Refinement statistics are summarized in Table 1. The quality of the structures was assessed using PROCHECK (30).

### Crystal structure of C-type lectin receptor DCAR

**Synthesis of IPM2**

The IPM2 analog having d-myo-inositol 1-phosphate was chemically synthesized from d-mannose and commercially available d-glucose derivative. First, d-myo-inositol acceptor was prepared from methyl α-D-glucopyranoside via 10 reaction steps according to the literature (31). Moffat oxidation of the primary alcohol of 2,3,4-tri-O-benzyl-protected glucoside, which was derived from methyl α-D-glucopyranoside via three steps, followed by treatment with acetic anhydride provided the Z-olefin product in good yields. Subsequent treatment of the olefin with palladium chloride afforded the 3-OH penta-oxigenated cyclohexanone derivative. The reduction of the resulting cyclic ketone with Me₄NBH(OAc)₃ provided the diol derivative of d-myo-inositol, which was then converted into the inositol diol acceptor with the allyl group at the C-1 position via three steps. On the other hand, 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate donor to be coupled with the inositol acceptor was readily prepared from d-mannose via seven steps. The glycosylation of the inositol acceptor with the mannose donor was performed in the presence of trimethyl trifluoromethanesulfonate in diethyl ether at 0 °C, affording the dimannoside in good yield and α-selectivity. Removal of the allyl group was then conducted by treatment of the dimannoside with Ir complex under hydrogen atmosphere in THF followed by hydrolysis with aqueous HCl, giving the alcohol in 93% yield. The phosphoester linkage was introduced to the C-1 position of the inositol residue by coupling with dibenzyl N,N-diisopropylphosphoramidite and 1H-tetrazole in CH₂Cl₂ and subsequent m-CPBA oxidation, affording the fully protected IPM2 analog in 84% yield. The final steps involved deacetylation and hydrogenolytic debenzylation to furnish the target IPM2 analog in good yields. The structure of IPM2 was verified by NMR and MS (Fig. S5–S8).

**Binding assay**

Mouse DCAR–Ig fusion proteins (WT and mutants) were generated as previously described (32). In brief, the extracellular domain of DCAR (residues 42–209) was fused to the N-terminal end of the hlgG1 Fc region. Fusion proteins were then incubated with increasing amounts of plate-coated AcPIMs (10, 30, and 100 ng/ml), and bound proteins were detected using horseradish peroxidase–labeled anti-human IgG (Jackson ImmunoResearch). After the addition of the chromogenic substrate, peroxidase activity was measured using a spectrophotometer. The mutant Ig fusion proteins were generated by recombinant PCR (primers are shown in Table S1).

**Reporter assay**

2B4-NFAT-GFP reporter cells were prepared as previously described (32). Briefly, we induced stable expression of FcRγ and DCAR or its mutants (generated by recombinant PCR; primers are shown in Table S1), and the cells were stimulated with increasing amounts of plate-coated AcPIMs (30, 100 and 300 ng/ml) or anti-mouse DCAR rat mAb (MAB2757, clone 349214, R&D Systems; 0.3, 1, and 3 μg/ml). GFP expression was then assessed by flow cytometry.
Crystal structure of C-type lectin receptor DCAR

Biolayer interferometry

The Octet RED96 System (forteBio, Pall Life Science) was used to measure the binding kinetics of DCAR—Ig fusion proteins to the synthetic AcPIM phosphosaccharide moiety, IPM2. The binding is measured by the shift of wavelength caused by the interaction between the two molecules on the surface of the biosensor. All assays were carried out at 25 °C on a black 96-well plate (Greiner, Bio-One), with agitation set at 1000 rpm and 200 µl/well for each solution. Super streptavidin biosensors (forteBio, Pall Life Science) were prewetted in TSM buffer (20 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM CaCl₂, 2 mM MgCl₂) for 10 min. The CaptureSelect™ Biotin anti-IgG–Fc conjugate (Thermo Fisher) was then loaded onto the biosensors to saturation (2 µg/ml in TSM buffer). Capture of the DCAR—Ig fusion protein (100 µg/ml in TSM buffer) was performed to saturation as well. Association to IPM2 was followed for 60 s and dissociation for 90 s. 2-fold concentration gradient of the compound was used in a titration series of six. Baseline drift was corrected by subtracting the shift of a sensor loaded with fusion protein but incubated in buffer only. Nonspecific binding was assessed by performing the assay with the Fc portion of human IgG (lg). Octet data were analyzed and processed using the Octet data analysis 11.1 software.

Author contributions—Z. O. and S. Y. conceptualization; S. Y. supervision; Z. O., Y. H., M. N., K. Toyonaga, and A. I. investigation; Z. O., Y. H., M. N., K. Toyonaga, and S. Y. writing—original draft; Z. O., Y. H., M. N., K. Toyonaga, and S. Y. writing—review and editing; A. I., K. Takato, T. T., and H. I. resources; T. T., Y. H., M. N., K. Toyonaga, and S. Y. writing—original draft; Z. O., Y. H., M. N., K. Toyonaga, and A. I. investigation; Z. O., Y. H., M. N., K. Toyonaga, and A. I. visualization; Z. O., Y. H., M. N., K. Toyonaga, and A. I. investigation; Z. O., Y. H., M. N., K. Toyonaga, and A. I. supervision.

Acknowledgments—We thank C. Motozono, T. Shimamurua, T. Seguchi, F. Sugihara, the staff of the Central instrumentation laboratory of the Research Institute for Microbial Diseases, Osaka University, and the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University for technical assistance and discussion. We thank the staff members of SPring-8 for help with data collection. This research was undertaken in part using Beamline BL45XU at SPring-8, Hyogo, Japan.

References
1. Akira, S., Uematsu, S., and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell 124, 783–801 CrossRef Medline
2. Hoving, J. C., Wilson, G. J., and Brown, G. D. (2014) Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol. 16, 185–194 CrossRef Medline
3. Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hermandez-Falcon, P., Rosewell, J., and Reis e Sousa, C. (2009) Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899–903 CrossRef Medline
4. Nagata, M., Iizumi, Y., Ishikawa, E., Kiyotake, R., Doi, R., Iwai, S., Omahdi, Z., Yamaji, T., Miyamoto, T., Bamba, T., and Yamasaki, S. (2017) Intracellular metabolite β-glucohydrolase is an endogenous Mincle ligand possessing immunostimulatory activity. Proc. Natl. Acad. Sci. U.S.A. 114, E3285–E3294 CrossRef Medline
5. Zelenksy, A., and Gready, J. E. (2005) The C-type lectin-like domain superfamily. FEBS J. 272, 6179–6217 CrossRef Medline
6. Kanazawa, N., Tashiro, K., Inaba, K., and Miyachi, Y. (2003) Dendritic cell immunoactivating receptor, a novel C-type lectin immunoreceptor, acts as an activating receptor through association with Fc receptor γ chain. J. Biol. Chem. 278, 32645–32652 CrossRef Medline
7. Toyonaga, K., Torigoe, S., Motomura, Y., Kamichi, T., Hayashi, J. M., Morita, Y. S., Noguchi, N., Chuma, Y., Kiyohara, H., Matsuo, K., Tanaka, H., Nakagawa, Y., Sakuma, T., Ohmuraya, M., Yamamoto, T., et al. (2016) C-type lectin receptor DCAR recognizes mycobacterial phosphatidyl-inositol mannosides to promote a Th1 response during infection. Immunity 45, 1245–1257 CrossRef Medline
8. Guerin, M. E., Kordulková, J., Alzari, P. M., Brennan, P. J., and Jackson, M. (2010) Molecular basis of phosphatidyl-myoinositol mannoside biosynthesis and regulation in mycobacteria. J. Biol. Chem. 285, 33577–33583 CrossRef Medline
9. Kerscher, B., Willment, J. A., and Brown, G. D. (2013) The Dectin-2 family of C-type lectin-like receptors: an update. Int. Immunol. 25, 271–277 CrossRef Medline
10. Flornes, L. M., Bryceson, Y. T., Spurkland, A., Lorentzen, J. C., Dissen, E., and Fossum, S. (2004) Identification of lectin-like receptors expressed by antigen presenting cells and neutrophils and their mapping to a novel gene complex. Immunogenetics 56, 506–517 CrossRef Medline
11. Feinberg, H., Jéguoso, S. A., Rowntree, T. J., Guan, Y., Brash, M. A., Taylor, M. E., Weis, W. I., and Drickamer, K. (2013) Mechanism for recognition of an unusual mycobacterial glycolipid by the macrophage receptor Mincle. J. Biol. Chem. 288, 28457–28465 CrossRef Medline
12. Drickamer, K. (1992) Engineering galactose-binding activity into a C-type mannose-binding protein. Nature 360, 183–186 CrossRef Medline
13. Nagae, M., Ikeda, A., Hanashima, S., Kojima, T., Matsumoto, N., Yamamoto, K., and Yamaguchi, Y. (2016) Crystal structure of human dendritic cell inhibitory receptor C-type lectin domain reveals the binding mode with N-glycan. FEBS Lett. 590, 1522–1528 CrossRef Medline
14. Feinberg, H., Rambaruth, N. D., Jéguoso, S. A., Jacobsen, K. M., Djurhuus, R., Poulsen, T. B., Weis, W. I., Taylor, M. E., and Drickamer, K. (2016) Binding sites for acylated trehalose analogs of glycolipid ligands on an extended carbohydrate recognition domain of the macrophage receptor Mincle. J. Biol. Chem. 291, 21222–21233 CrossRef Medline
15. Nagae, M., Yamakana, K., Hanashima, S., Ikeda, A., Morita-Matsumoto, K., Satoh, T., Matsumoto, N., Yamamoto, K., and Yamaguchi, Y. (2013) Recognition of bisecting N-acetylglcosaminae: structural basis for asymmetric interaction with the mouse lectin dendritic cell inhibitory receptor 2. J. Biol. Chem. 288, 33598–33610 CrossRef Medline
16. Feinberg, H., Jéguoso, S. A. F., Rex, M. J., Drickamer, K., Weis, W. I., and Taylor, M. E. (2017) Mechanism of pathogen recognition by human dectin-2. J. Biol. Chem. 292, 13402–13414 CrossRef Medline
17. Jéguoso, S. A., Feinberg, H., Dungarwalla, T., Drickamer, K., Weis, W. I., and Taylor, M. E. (2015) A novel mechanism for binding of galactose-terminated glycan by the C-type carbohydrate recognition domain in blood dendritic cell antigen 2. J. Biol. Chem. 290, 16759–16771 CrossRef Medline
18. Nagae, M., Ikeda, A., Kitago, Y., Matsumoto, N., Yamamoto, K., and Yamaguchi, Y. (2014) Crystal structures of carbohydrate recognition domain of blood dendritic cell antigen-2 (BDCA2) reveal a common domain-swapped dimer. Proteins 82, 1512–1518 CrossRef Medline
19. Liongue, C., Sertori, R., and Ward, A. C. (2016) Evolution of cytokine receptor signaling. J. Immunol. 197, 11–18 CrossRef Medline
20. Pelka, K., Shibata, T., Miyake, K., and Latz, E. (2016) Nuclear acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology. Immuno. Rev. 269, 60–75 CrossRef Medline
21. Haurum, J. S., Thiels, S. H., Haagsman, H. P., Laursen, S. B., Larsen, B., and Jensenius, J. C. (1993) Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: mannan-binding protein and conglutinin. Biochem. J. 293, 837–878 CrossRef Medline
22. Poget, S. F., Legge, G. B., Proctor, M. R., Butler, P. J., Bycroft, M., and Williams, R. L. (1999) The structure of a tunicle C-type lectin from Polyandrocara misakensis complexed with κ-galactose. J. Mol. Biol. 290, 867–879 CrossRef Medline
23. Furukawa, A., Kamishikiryo, J., Mori, D., Toyonaga, K., Okabe, Y., Toji, A., Kanda, R., Miyake, Y., Ose, T., Yamasaki, S., and Maenaka, K. (2013) Structural analysis for glycolipid recognition by the C-type lectins Mincle and MCL. Proc. Natl. Acad. Sci. U.S.A. 110, 17438–17443 CrossRef Medline
Crystal structure of C-type lectin receptor DCAR

24. Goodridge, H. S., Reyes, C. N., Becker, C. A., Katsumoto, T. R., Ma, J., Wolf, A. J., Bose, N., Chan, A. S., Magee, A. S., Danielson, M. E., Weiss, A., Vasilakos, J. P., and Underhill, D. M. (2011) Activation of the innate immune receptor Dectin-1 upon formation of a "phagocytic synapse." Nature 472, 471–475

25. Iborra, S., and Sancho, D. (2015) Signalling versatility following self and non-self sensing by myeloid C-type lectin receptors. Immunobiology 220, 175–184

26. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132

27. Vagin, A., and Teplyakov, A. (2000) An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56, 1622–1624

28. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132

29. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255

30. Vaguine, A. A., Richelle, J., and Wodak, S. J. (1999) SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure–factor data and their agreement with the atomic model. Acta Crystallogr. D Biol. Crystallogr. 55, 191–205

31. Takahashi, H., Kittaka, H., and Ikekami, S. (2001) Novel synthesis of enantiomerically pure natural inositols and their diastereoisomers. J. Org. Chem. 66, 2705–2716

32. Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K., and Saito, T. (2008) Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat. Immunol. 9, 1179–1188

33. Gouet, P., Robert, X., and Courcelle, E. (2003) ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 31, 3320–3323